Leap Therapeutics, Inc. (NASDAQ: LPTX) rose Thursday, following news of updated results for its DKN-01 plus tislelizumab showed 'compelling' activity in first-line patients with gastric, gastroesophageal junction cancer.
The Company announced positive initial data from the DisTinGuish study on Monday, September 13, based on 25 G/GEJ patients enrolled in the trial that showed DKN-01 in combination with tislelizumab and chemotherapy as first-line therapy was well tolerated with compelling activity.
The results presented at the ESMO Congress today included additional patient data stratified by tumoral PD-L1 expression levels based on visually-estimated combined positive score (vCPS), showing that robust objective clinical responses can be achieved from this combination regimen independently of PD-L1 expression.
"Initial data from this trial have shown that patients with high levels of DKK1 expression, a group with a poor prognosis, had encouraging responses to treatment. The additional data presented today show evidence that not only is DKK1 a critical biomarker in predicting response to DKN-01 and tislelizumab therapy, but also that the combination can induce deep responses regardless of the patient's PD-L1 status, including particularly poor prognosis patients with both low PD-L1 and high DKK1 ," said Samuel Klempner , MD, Member of the Faculty at Massachusetts General Hospital Cancer Center and Harvard Medical School .
"Taken together, these are promising results for the combination therapy of DKN-01 with tislelizumab and chemotherapy in first line patients with gastric or gastroesophageal junction cancers."
LPTX shares jumped 37 cents, or 19.2%, to $2.30
